Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 7331-7340 Newer>

The Motley Fool April 14, 2011 Arlene Weintraub	Acorda Stock Halted as Shares Skyrocket on Patent Speculation RBC Capital Markets are suggesting good things for the company's MS drug.
The Motley Fool April 14, 2011 Brian Orelli	One Step Closer to Revenue for Delcath But, between getting the Chemostat paid for in Europe and approved stateside, there's still plenty for Delcath to be worried about.
The Motley Fool April 14, 2011 Brian Orelli	Human Genome Sciences Will Be Profitable, Eventually With its first drug on the market -- nearly 20 years after the company was founded -- Human Genome Sciences should start to show meaningful revenue this year.
The Motley Fool April 14, 2011 Frank Vinluan	Biogen Idec Inks Biotech Blood Products Research Deal With Amunix The exclusive, worldwide research collaboration agreement calls for both companies to jointly conduct preclinical research.
The Motley Fool April 13, 2011 Brian Orelli	Drug Duo Escapes Advisory Panel Unharmed Pfizer and Novartis are on their way to expanding their cancer drug indications.
The Motley Fool April 13, 2011 Brian Orelli	Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients.
The Motley Fool April 12, 2011 Brian Orelli	Delcath's Disappointing Delay The company said it will need an additional three months to resubmit the marketing application for its chemotherapy system.
The Motley Fool April 12, 2011 Brian Orelli	Merck Joins the Low-Margin Party The American drugmaker announces that it is partnering with Sun Pharma to establish a joint venture to sell branded generics in emerging markets.
The Motley Fool April 12, 2011 Brian Orelli	How Significant Is 'Statistically Significant' for Biogen? Biogen could have a third multiple sclerosis blockbuster on its hands.
The Motley Fool April 12, 2011 Arundhati Parmar	Endo Acquires Pelvic Care Firm American Medical Systems The company that began life in the pharmaceutical sector is venturing forth into devices in its quest to become more of a diversified health-care company.
<Older 7331-7340 Newer> Return to current articles.